Skip to main content

Remote Job Finders (RJF)

Is Revolution ‘the next oncology titan’? Truist analysts make the case

A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter.

Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B

Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a new drug class to its early-stage pipeline.
Scroll to top